Heat Biologics, Inc. Commences Patient Dosing of Phase 2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer

DURHAM, N.C., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX ), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has initiated patient dosing in its Phase 2 clinical trial of vesigenurtacel-L ( HS-410 ) in subjects with high-risk, non-muscle invasive bladder cancer. Vesigenurtacel-L is Heat's investigational drug in a series of proprietary Immune Pan Antigen Cytotoxic Therapy (" ImPACT ") based allogeneic cell lines designed to direct killer T cells to attack cancer. The primary endpoint for the Phase 2 portion of the bladder cancer study is one-year disease-free survival.

The multi-center Phase 2 portion of Heat's bladder cancer study is designed to determine whether vaccination with one of two doses of vesigenurtacel-L in combination with Bacillus Calmette-Guérin (BCG) after transurethral resection of bladder tumor (TURBT) increases disease-free survival at one year compared to BCG in combination with placebo. The blinded, randomized placebo-controlled study will enroll approximately 75 patients.  Heat expects to complete patient enrollment of the Phase 2 study in the third quarter of 2015 and report topline results in third quarter of 2016.

"We have made substantial progress executing on our clinical strategy over the course of the year, specifically advancing our two lead product candidates for lung and bladder cancers into Phase 2 development," said Jeff Wolf, Chief Executive Officer of Heat Biologics. "The start of patient dosing of vesigenurtacel-L for bladder cancer, a full quarter ahead of schedule, is a major milestone for Heat and a clear example of the team's commitment to operational excellence."

Mr. Wolf concluded, "By accelerating the bladder cancer program into Phase 2, we are now well positioned to provide the disease-free survival data ahead of schedule and are another step closer to fulfilling a true unmet need for bladder cancer patients with the potential of providing a new, viable and effective treatment."

Patient enrollment and dosing in the vesigenurtacel-L Phase 2 study for the treatment of bladder cancer is expected to be completed in the third quarter of 2015. The Company anticipates reporting top-line results in the third quarter of 2016 after the study's twelve-month patient observation period concludes.

For patients and physicians interested in enrollment information for the Phase 2 portion of the study of vesigenurtacel-L in patients with high-risk non-muscle invasive bladder cancer, please visit clinicaltrials.gov and use Identifier NCT02010203 .

About Bladder Cancer

According to the American Cancer Society, in 2014, there will be 74,690 new bladder cancer diagnoses and 15,580 deaths from the disease in the U.S. alone.  More than 500,000 people in the U.S. have been treated for bladder cancer.  Importantly, the U.S. Food and Drug Administration (FDA) has not approved any new drugs to treat bladder cancer in more than 25 years.  Heat's vesigenurtacel-L (HS‑410) represents a viable opportunity to address a significant unmet medical need.

About Vesigenurtacel-L ( HS-410 )

Vesigenurtacel-L (HS-410) is an investigational biologic originating from Heat's proprietary Immune Pan Antigen Cytotoxic Therapy ( ImPACT ) based allogeneic cell lines designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer. ImPACT Therapy reprograms live cancer cells from a single tumor source to continually secrete gp96, a chaperone protein found in all human cells. In turn, gp96 chaperones tumor antigens to T-cells to activate a robust, pan-antigen T-cell immune response and direct killer T-cells to attack the patient's cancer.

About the Vesigenurtacel-L ( HS-410 ) Phase 1/2 Study

The multi-center Phase 1/2 study will enroll approximately 84 patients with non-muscle invasive bladder cancer and is designed to determine whether vaccination with vesigenurtacel-L after transurethral resection of bladder tumor (TURBT) extends the disease-free interval compared to placebo. The trial will also test the safety and immune response of vesigenurtacel-L in bladder cancer patients.

About Heat Biologics, Inc.

Heat Biologics, Inc. ( www.heatbio.com ) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT  therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat's viagenpumatucel-L ( HS-110 ) is being evaluated in a Phase 2 trial in patients with non-small cell lung cancer and its vesigenurtacel-L ( HS-410 ) is being evaluated in an ongoing Phase 1/2 clinical trial against bladder cancer.

Forward Looking Statements

This press release includes forward-looking statements on our current expectations and projections about future events.  In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the expected completion date of enrollment and dosing of the Phase 2 study, the date of release of top-line results, the market size and the potential for Heat's ImPACT Therapy.  These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed, and ability to enroll patients as planned, and the other factors described in our annual report on Form 10-K for the year ended December 31, 2013 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Heat Biologics, Inc. Contact Information: Matthew Czajkowski Chief Financial Officer (919) 240 7133 Jenene Thomas Investor Relations and Corporate Communications Advisor Jenene Thomas Communications, LLC (908) 938-1475

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 222

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 139

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaking News: Sportswear Highlights and Streaming Drama Unfolds

Updated Category News Views 235

New On The Block Puma SE, a Germany-based sportswear company, is drawing interest from several buyers in Asia. Notable bids are coming from China's Anta Sports and Li Ning Co., alongside Japan's Asics Corp. As the market responds to this potential sale, the implications for both Puma and the interested firms may shift the dynamics in the sportswear industry. The Netflix...

Continue Reading
Bridging the AI Adoption Gap for Modern Enterprises

Updated Category News Views 103

Navigating the Challenges of AI Adoption in Enterprises In today's fast-paced business landscape, the integration of artificial intelligence (AI) has become more crucial than ever. A recent survey conducted by Unily highlights a pressing concern: many enterprises are struggling to keep pace with AI adoption. The findings reveal that nearly 40% of employees feel their...

Continue Reading
Cryptocurrency Market Trends: Key Insights on Bitcoin and More

Updated Category News Views 393

Cryptocurrency Market Holds Steady Amid Economic Shifts Recently, the cryptocurrency market has shown remarkable stability despite fluctuating stock indices. As economic factors shift, particularly with recent job data revisions, market expectations for interest rate changes have intensified. Bitcoin Sees Minor Decline Bitcoin momentarily surged past $113,000 before...

Continue Reading
Exploring Earnings Insights for Stantec's Upcoming Report

Updated Category News Views 77

Stantec's Upcoming Earnings Report Overview Stantec (NYSE: STN) is preparing to release its latest quarterly earnings report soon. Investors are gearing up in anticipation of what this report might reveal about the company's financial health and future outlook. Analysts' Earnings Predictions Experts are estimating that Stantec will announce an earnings per share (EPS) of...

Continue Reading
Yarbo Unleashes the M Series: Transforming Yard Care

Updated Category News Views 45

Dust off your lawn chairs, folks, because Yarbo is strutting into IFA 2026 with its M Series, a real game-changer in yard robotics. These aren't just fancy grass clippers; they're smart machines turning yard care on its head. Ever wrestle with a rake or push a lawn mower when you'd rather be soaking in some sun? Well, you're in luck. From Dream to Dirt: M Series Arrives...

Continue Reading